ReActiv8 Implantable Neurostimulation System
Mainstay Medical Limited · Decision date Jun 16, 2020
What did the FDA approve?
FDA approved PMA P190021 for the ReActiv8 Implantable Neurostimulation System on June 16, 2020. The approval covers bilateral stimulation of the L2 medial branch of the dorsal ramus where it crosses the transverse process at L3, as an aid in managing intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed pain medications and physical therapy and are not candidates for spine surgery.
The device is classified as a totally implanted neuromuscular stimulator for lower back muscles, product code QLK, under the neurology specialty. The applicant is Mainstay Medical Limited. The approval statement describes the intended patient population and stimulation target but does not itself provide independent proof of safety or clinical effectiveness.
FDA approval order statement
Approval for the ReActiv8 System is indicated for bilateral stimulation of the L2 medial branch of the dorsal ramus as it crosses the transverse process at L3 as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy and are not candidates for spine surgery.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jun 16, 2020
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190021
- Regulatory pathway
- Premarket approval application
- Applicant
- Mainstay Medical Limited
- Product code
- QLK
- Decision code
- APPR
- Decision date
- Jun 16, 2020
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief.
- Applicant
- Mainstay Medical Limited
- Product code
- QLK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P190021 received
Application receipt date recorded by FDA.
P190021 · FDA decision
APPR
P190021/S012 · Related supplement
ReActiv8 Implantable Neurostimulation System
Timeline entries are records held by MedtechLedger for P190021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ReActiv8 Implantable Neurostimulation SystemP190021/S012 | Mainstay Medical Limited | PMA supplement | Oct 19, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Mainstay Medical Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Clonmel House Forster Way, Swords, Co Dublin, K67F2K3
Sources and methodology
- Original FDA record: P190021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records